Prognostic role of genetic biomarkers in clinical progression of prostate cancer
Open Access
- 7 August 2015
- journal article
- research article
- Published by Springer Nature in Experimental & Molecular Medicine
- Vol. 47 (8) , e176
Abstract
The aim of this study was to analyze the use of 12 single-nucleotide polymorphisms in genes ELAC2, RNASEL and MSR1 as biomarkers for prostate cancer (PCa) detection and progression, as well as perform a genetic classification of high-risk patients. A cohort of 451 men (235 patients and 216 controls) was studied. We calculated means of regression analysis using clinical values (stage, prostate-specific antigen, Gleason score and progression) in patients and controls at the basal stage and after a follow-up of 72 months. Significantly different allele frequencies between patients and controls were observed for rs1904577 and rs918 (MSR1 gene) and for rs17552022 and rs5030739 (ELAC2). We found evidence of increased risk for PCa in rs486907 and rs2127565 in variants AA and CC, respectively. In addition, rs627928 (TT–GT), rs486907 (AG) and rs3747531 (CG–CC) were associated with low tumor aggressiveness. Some had a weak linkage, such as rs1904577 and rs2127565, rs4792311 and rs17552022, and rs1904577 and rs918. Our study provides the proof-of-principle that some of the genetic variants (such as rs486907, rs627928 and rs2127565) in genes RNASEL, MSR1 and ELAC2 can be used as predictors of aggressiveness and progression of PCa. In the future, clinical use of these biomarkers, in combination with current ones, could potentially reduce the rate of unnecessary biopsies and specific treatments.Keywords
This publication has 24 references indexed in Scilit:
- SNP-SNP Interaction Network in Angiogenesis Genes Associated with Prostate Cancer AggressivenessPLOS ONE, 2013
- The Role of Genetic Markers in the Management of Prostate CancerEuropean Urology, 2012
- International Variation in Prostate Cancer Incidence and Mortality RatesEuropean Urology, 2012
- Single and Multivariate Associations of MSR1, ELAC2, and RNASEL with Prostate Cancer in an Ethnic Diverse Cohort of MenCancer Epidemiology, Biomarkers & Prevention, 2010
- Analysis of the RNASEL/HPC1, and Macrophage Scavenger Receptor 1 in Asian-Indian Advanced Prostate CancerUrology, 2008
- DNA Variation in MSR1, RNASEL and E-Cadherin Genes and Prostate Cancer in PolandUrologia Internationalis, 2007
- Diverse functions of RNase L and implications in pathologyBiochimie, 2007
- Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10 ng/ml: Systematic Review and Meta-AnalysisEuropean Urology, 2005
- Molecular pathology of prostate cancerJournal of Clinical Pathology, 2005
- The missense mutations in the candidate prostate cancer gene ELAC2 do not alter enzymatic properties of its productCancer Letters, 2005